T 1126/19 (Rucaparib camsylate/PFIZER) of 21.07.2023

European Case Law Identifier: ECLI:EP:BA:2023:T112619.20230721
Date of decision: 21 July 2023
Case number: T 1126/19
Petition for review of: -
Application number: 11708094.5
IPC class: A61K 45/06 A61K 31/55 C07C 309/19 C07C 57/145 C07D 487/06
Language of proceedings: English
Distribution: No distribution (D)
Download: Decision in English
OJ versions: No OJ links found
Other decisions for this case: -
Abstracts for this decision: Abstract on EPC2000 Art 056
Application title: SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO}METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE
Applicant name: Pfizer Inc.
Opponent name: Hamm&Wittkopp Patentanwälte PartmbB
Hexal AG
Board: 3.3.07
Headnote: -
Relevant legal provisions: European Patent Convention Art 54 European Patent Convention Art 56
Keywords: Novelty - implicit disclosure (no)
Inventive step - non-obvious solution
Catchword: -
Cited cases: T 0970/00 T 0777/08 T 1555/12 T 0041/17
Citing cases: T 0243/22 T 0295/22 T 0356/22 T 0749/23

Order

For these reasons it is decided that:

The appeals are dismissed.